TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials

被引：127

作者：

Choucair, Khalil ^{[1
]}

Morand, Susan ^{[2
]}

Stanbery, Laura ^{[2
]}

Edelman, Gerald ^{[2
]}

Dworkin, Lance ^{[2
]}

Nemunaitis, John ^{[2
]}

机构：

[1] Univ Kansas, Sch Med, Dept Internal Med, Wichita, KS 67214 USA

[2] Univ Toledo, Coll Med & Life Sci, Dept Med, 2801 W Bancroft St, Toledo, OH 43606 USA

来源：

CANCER GENE THERAPY | 2020年 / 27卷 / 12期

关键词：

TUMOR MUTATIONAL BURDEN; CHECKPOINT BLOCKADE THERAPY; PD-1; BLOCKADE; CTLA-4; OPEN-LABEL; CLINICAL-RESPONSE; CANCER; NIVOLUMAB; RESISTANCE; PEMBROLIZUMAB;

D O I：

10.1038/s41417-020-0174-y

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Immune checkpoint inhibition (ICI) has revolutionized cancer treatment, and produced durable responses in many cancer types. However, there remains a subset of patients that do not respond despite their tumors exhibiting PD-L1 expression, which highlights the need for additional biomarkers relevant to response. Here, we review checkpoint inhibitor signal pathways, resistance and sensitivity mechanisms, as well as response rates. We also investigate the correlation and response to ICI with BRCA1/2 mutation status and homologous recombination deficient tumors. Collectively we show that the use of tumor mutational burden may be effective as an emerging biomarker.

引用

页码：841 / 853

页数：13

共 133 条

[1] Signatures of mutational processes in human cancer [J].

Alexandrov, Ludmil B. ;

Nik-Zainal, Serena ;

Wedge, David C. ;

Aparicio, Samuel A. J. R. ;

Behjati, Sam ;

Biankin, Andrew V. ;

Bignell, Graham R. ;

Bolli, Niccolo ;

Borg, Ake ;

Borresen-Dale, Anne-Lise ;

Boyault, Sandrine ;

Burkhardt, Birgit ;

Butler, Adam P. ;

Caldas, Carlos ;

Davies, Helen R. ;

Desmedt, Christine ;

Eils, Roland ;

Eyfjord, Jorunn Erla ;

Foekens, John A. ;

Greaves, Mel ;

Hosoda, Fumie ;

Hutter, Barbara ;

Ilicic, Tomislav ;

Imbeaud, Sandrine ;

Imielinsk, Marcin ;

Jaeger, Natalie ;

Jones, David T. W. ;

Jones, David ;

Knappskog, Stian ;

Kool, Marcel ;

Lakhani, Sunil R. ;

Lopez-Otin, Carlos ;

Martin, Sancha ;

Munshi, Nikhil C. ;

Nakamura, Hiromi ;

Northcott, Paul A. ;

Pajic, Marina ;

Papaemmanuil, Elli ;

Paradiso, Angelo ;

Pearson, John V. ;

Puente, Xose S. ;

Raine, Keiran ;

Ramakrishna, Manasa ;

Richardson, Andrea L. ;

Richter, Julia ;

Rosenstiel, Philip ;

Schlesner, Matthias ;

Schumacher, Ton N. ;

Span, Paul N. ;

Teague, Jon W. .

NATURE, 2013, 500 (7463) :415-+

[2] Progressive Loss of Memory T Cell Potential and Commitment to Exhaustion during Chronic Viral Infection [J].

Angelosanto, Jill M. ;

Blackburn, Shawn D. ;

Crawford, Alison ;

Wherry, E. John .

JOURNAL OF VIROLOGY, 2012, 86 (15) :8161-8170

[3]

[Anonymous], 2019, P 50 ANN M SOC GYN O

[4]

[Anonymous], FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication

[5] Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial [J].

Antonia, Scott J. ;

Lopez-Martin, Jose A. ;

Bendell, Johanna ;

Ott, Patrick A. ;

Taylor, Matthew ;

Eder, Joseph Paul ;

Jaeger, Dirk ;

Pietanza, M. Catherine ;

Le, Dung T. ;

de Braud, Filippo ;

Morse, Michael A. ;

Ascierto, Paolo A. ;

Horn, Leora ;

Amin, Asim ;

Pillai, Rathi N. ;

Evans, Jeffry ;

Chau, Ian ;

Bono, Petri ;

Atmaca, Akin ;

Sharma, Padmanee ;

Harbison, Christopher T. ;

Lin, Chen-Sheng ;

Christensen, Olaf ;

Calvo, Emiliano .

LANCET ONCOLOGY, 2016, 17 (07) :883-895

[6] IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade [J].

Ayers, Mark ;

Lunceford, Jared ;

Nebozhyn, Michael ;

Murphy, Erin ;

Loboda, Andrey ;

Kaufman, David R. ;

Albright, Andrew ;

Cheng, Jonathan D. ;

Kang, S. Peter ;

Shankaran, Veena ;

Piha-Paul, Sarina A. ;

Yearley, Jennifer ;

Seiwert, Tanguy Y. ;

Ribas, Antoni ;

McClanahan, Terrill K. .

JOURNAL OF CLINICAL INVESTIGATION, 2017, 127 (08) :2930-2940

[7] Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial [J].

Balar, Arjun V. ;

Galsky, Matthew D. ;

Rosenberg, Jonathan E. ;

Powles, Thomas ;

Petrylak, Daniel P. ;

Bellmunt, Joaquim ;

Loriot, Yohann ;

Necchi, Andrea ;

Hoffman-Censits, Jean ;

Perez-Gracia, Jose Luis ;

Dawson, Nancy A. ;

van der Heijden, Michiel S. ;

Dreicer, Robert ;

Srinivas, Sandy ;

Retz, Margitta M. ;

Joseph, Richard W. ;

Drakaki, Alexandra ;

Vaishampayan, Ulka N. ;

Sridhar, Srikala S. ;

Quinn, David I. ;

Duran, Ignacio ;

Shaffer, David R. ;

Eigl, Bernhard J. ;

Grivas, Petros D. ;

Yu, Evan Y. ;

Li, Shi ;

Kadel, Edward E., III ;

Boyd, Zachary ;

Bourgon, Richard ;

Hegde, Priti S. ;

Mariathasan, Sanjeev ;

Thastrom, AnnChristine ;

Abidoye, Oyewale O. ;

Fine, Gregg D. ;

Bajorin, Dean F. .

LANCET, 2017, 389 (10064) :67-76

[8]

Baras AS, 2017, CANC RES S13, V77

[9]

Barve M, 2017, MOL MED CURR ASP S1, V1, P5

[10] PD-L1 Expression as a Predictive Biomarker Is Absence of Proof the Same as Proof of Absence? [J].

Bhaijee, Feriyl ;

Anders, Robert A. .

JAMA ONCOLOGY, 2016, 2 (01) :54-55

← 1 2 3 4 5 6 7 8 9 10 →